The Lancet’s Post

Every time I see scientific magazines publishing news of disease progression treatments, I search for the the cost-benefits discussions of these advancements to societies such as Brazilian. You really don’t have to go too far: “For many patients globally, these developments will make no difference to their prognosis. - Many of these new drugs are hugely expensive, making them unaffordable in much of the world, and access to diagnosis and tumor profiling is often still limited. - The need for a better public health approach to lung cancer remains paramount. - Tobacco smoking is still the biggest risk factor for lung cancer, and smoking rates continue to increase in young people (…). Primary prevention, particularly through strong tobacco control, is crucial.” Lots of discussions here 😉 #prevention #stress

🔬 Major Breakthrough Alert! 🔬 Mayo Clinic's latest research unveils new gene markers that could revolutionize the way we detect Lynch syndrome-associated colorectal cancer. 🙌 Early detection is crucial, and this discovery brings us one step closer to more effective screening and treatment. 💪 Read the full story: https://lnkd.in/dF3kpB_V Let's spread the word and raise awareness about this game-changing development in cancer research! 🎗️ #CancerResearch #LynchSyndrome #ColorectalCancer #MedicalBreakthrough #MayoClinic #Researchanddevelopment #SCLAManagement

This #FridayRead highlights the value of Immunologic Constant of Rejection signature (ICR) as a potential biomarker for the effectiveness of anti-PD1/PDL1 in lung cancer 👉 https://bit.ly/462pBgP Groups at APHM (Assistance Publique - Hopitaux de Marseille) and Institut Paoli-Calmettes identified a gene signature with a nCounter panel and revealed a strong link between the ICR classification and treatment response. 🔍 These results emphasize the impact of molecular signatures like ICR in tailoring personalized treatment strategies for cancer therapies. #GeneSignature #LungCancer #PrecisionMedicine

For #TrialTuesday, Alliance A022106/PLATINUM trial, led by Dr. Andrew Ko, of UCSF Helen Diller Family Comprehensive Cancer Center, compares two chemotherapy regimens to treat patients with metastatic #pancreaticcancer and BRCA1/2 or PALB2 gene mutation. To learn more about the PLATINUM trial, visit https://lnkd.in/gq9nYKxM #NCI #NCTN Pancreatic Cancer Action Network Let's Win Pancreatic Cancer #PancChat #PancSM

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.

Findings from the Phase III PARADIGM trial published in Nature Medicine on February 14, 2024, shed light on biomarker-driven treatment for metastatic colorectal cancer (mCRC). The trial demonstrated that patients with RAS wild-type mCRC and left-sided tumors showed longer overall survival with panitumumab plus mFOLFOX6. For this prespecified analysis, we designed and validated a custom CRC ctDNA assay using a comprehensive panel of gene alterations associated with resistance to anti-EGFR therapy. These exploratory biomarker results underscore the potential of ctDNA in guiding optimal treatment decisions for mCRC patients in the frontline setting.